Clinical Trial Update: A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase II study evaluating sintilimab as second-line therapy for biomarker-selected advanced or metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: China Medical University, China | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN